Kyle J. Seamon

1.6k total citations
17 papers, 535 citations indexed

About

Kyle J. Seamon is a scholar working on Molecular Biology, Virology and Infectious Diseases. According to data from OpenAlex, Kyle J. Seamon has authored 17 papers receiving a total of 535 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 4 papers in Virology and 3 papers in Infectious Diseases. Recurrent topics in Kyle J. Seamon's work include HIV Research and Treatment (4 papers), CRISPR and Genetic Engineering (3 papers) and Signaling Pathways in Disease (3 papers). Kyle J. Seamon is often cited by papers focused on HIV Research and Treatment (4 papers), CRISPR and Genetic Engineering (3 papers) and Signaling Pathways in Disease (3 papers). Kyle J. Seamon collaborates with scholars based in United States and Russia. Kyle J. Seamon's co-authors include James T. Stivers, Erik C Hansen, Luda S. Shlyakhtenko, Zhiqiang Sun, Yuri L. Lyubchenko, Karsten Gronert, Namandjé N. Bumpus, V. Mani, Edwin A. Saada and Joseph S. Schoeniger and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Nucleic Acids Research.

In The Last Decade

Kyle J. Seamon

17 papers receiving 530 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kyle J. Seamon United States	13	271	146	137	93	72	17	535
Geneviève Doyon United States	11	196 0.7×	156 1.1×	95 0.7×	72 0.8×	70 1.0×	18	527
Haifeng Song China	11	205 0.8×	101 0.7×	167 1.2×	165 1.8×	143 2.0×	33	560
Susan Harvey United Kingdom	14	160 0.6×	99 0.7×	152 1.1×	117 1.3×	87 1.2×	27	638
Mohammed Bouziane Morocco	13	353 1.3×	65 0.4×	60 0.4×	43 0.5×	117 1.6×	75	608
Xiumei Chi China	18	175 0.6×	40 0.3×	213 1.6×	504 5.4×	70 1.0×	53	917
Toshio Hattori Japan	8	256 0.9×	42 0.3×	172 1.3×	47 0.5×	27 0.4×	13	521
Zhongcheng Zou United States	10	362 1.3×	49 0.3×	396 2.9×	42 0.5×	135 1.9×	19	768
Charles Allen United States	13	92 0.3×	39 0.3×	108 0.8×	59 0.6×	41 0.6×	20	360
Paul Feucht United States	9	215 0.8×	44 0.3×	214 1.6×	53 0.6×	170 2.4×	11	597
J. Andrew Bristol United States	16	295 1.1×	20 0.1×	137 1.0×	78 0.8×	148 2.1×	20	626

Countries citing papers authored by Kyle J. Seamon

Since Specialization

Citations

This map shows the geographic impact of Kyle J. Seamon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyle J. Seamon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyle J. Seamon more than expected).

Fields of papers citing papers by Kyle J. Seamon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kyle J. Seamon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyle J. Seamon. The network helps show where Kyle J. Seamon may publish in the future.

Co-authorship network of co-authors of Kyle J. Seamon

This figure shows the co-authorship network connecting the top 25 collaborators of Kyle J. Seamon. A scholar is included among the top collaborators of Kyle J. Seamon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kyle J. Seamon. Kyle J. Seamon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Dilly, Julien, Eejung Kim, Lo Lai, et al.. (2025). Abstract 5507: Mechanisms of resistance to RAS-GTP inhibition in pancreatic cancer. Cancer Research. 85(8_Supplement_1). 5507–5507. 1 indexed citations

Seamon, Kyle J., et al.. (2024). Abstract 4709: The RASMULTI(ON) inhibitor RMC-7977 blocks downstream MAPK and PI3K pathway activation in KRASG12X_mutant cancers. Cancer Research. 84(6_Supplement). 4709–4709. 1 indexed citations

Knox, John E., G. Leslie Burnett, Caroline E. Weller, et al.. (2024). Abstract ND03: Discovery of RMC-9805, an oral, covalent tri-complex KRASG12D(ON) inhibitor. Cancer Research. 84(7_Supplement). ND03–ND03. 12 indexed citations

Nichols, Robert J., Yu Chi Yang, Jim Cregg, et al.. (2022). Abstract 3595: RMC-6291, a next-generation tri-complex KRASG12C(ON) inhibitor, outperforms KRASG12C(OFF) inhibitors in preclinical models of KRASG12C cancers. Cancer Research. 82(12_Supplement). 3595–3595. 27 indexed citations

Gustafson, W. Clay, David Wildes, Meghan A. Rice, et al.. (2022). Direct targeting of RAS in pancreatic ductal adenocarcinoma with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RAS^MULTI(ON) inhibitor.. Journal of Clinical Oncology. 40(4_suppl). 591–591. 23 indexed citations

Schulze, Christopher J., Jim Cregg, Kyle J. Seamon, et al.. (2022). Abstract 3598: A first-in-class tri-complex KRASG13C(ON) inhibitor validates therapeutic targeting of KRASG13Cand drives tumor regressions in preclinical models. Cancer Research. 82(12_Supplement). 3598–3598. 9 indexed citations

Christenson, Eric S., Anthony S. Gizzi, Kyle J. Seamon, et al.. (2021). Inhibition of Human Uracil DNA Glycosylase Sensitizes a Large Fraction of Colorectal Cancer Cells to 5-Fluorodeoxyuridine and Raltitrexed but Not Fluorouracil. Molecular Pharmacology. 99(6). 412–425. 8 indexed citations

Johnston, Robert K., Kyle J. Seamon, Edwin A. Saada, et al.. (2019). Use of anti-CRISPR protein AcrIIA4 as a capture ligand for CRISPR/Cas9 detection. Biosensors and Bioelectronics. 141. 111361–111361. 25 indexed citations

Seamon, Kyle J., Joseph S. Schoeniger, Brooke Harmon, et al.. (2019). Ultrasensitive multi-species detection of CRISPR-Cas9 by a portable centrifugal microfluidic platform. Analytical Methods. 11(5). 559–565. 23 indexed citations

10.

Seamon, Kyle J., Yooli Kim Light, Edwin A. Saada, Joseph S. Schoeniger, & Brooke Harmon. (2018). Versatile High-Throughput Fluorescence Assay for Monitoring Cas9 Activity. Analytical Chemistry. 90(11). 6913–6921. 17 indexed citations

11.

Seamon, Kyle J., Namandjé N. Bumpus, & James T. Stivers. (2016). Single-Stranded Nucleic Acids Bind to the Tetramer Interface of SAMHD1 and Prevent Formation of the Catalytic Homotetramer. Biochemistry. 55(44). 6087–6099. 36 indexed citations

12.

Seamon, Kyle J. & James T. Stivers. (2015). A High-Throughput Enzyme-Coupled Assay for SAMHD1 dNTPase. SLAS DISCOVERY. 20(6). 801–809. 29 indexed citations

13.

Seamon, Kyle J., Zhiqiang Sun, Luda S. Shlyakhtenko, Yuri L. Lyubchenko, & James T. Stivers. (2015). SAMHD1 is a single-stranded nucleic acid binding protein with no active site-associated nuclease activity. Nucleic Acids Research. 43(13). 6486–6499. 98 indexed citations

14.

Seamon, Kyle J., Erik C Hansen, Anastasia P. Kadina, et al.. (2014). Small Molecule Inhibition of SAMHD1 dNTPase by Tetramer Destabilization. Journal of the American Chemical Society. 136(28). 9822–9825. 28 indexed citations

15.

Hansen, Erik C, et al.. (2014). GTP activator and dNTP substrates of HIV-1 restriction factor SAMHD1 generate a long-lived activated state. Proceedings of the National Academy of Sciences. 111(18). E1843–51. 75 indexed citations

16.

Kalish, Brian T., Hau D. Le, Kyle J. Seamon, et al.. (2013). Intravenous fish oil lipid emulsion promotes a shift toward anti-inflammatory proresolving lipid mediators. American Journal of Physiology-Gastrointestinal and Liver Physiology. 305(11). G818–G828. 40 indexed citations

17.

Seamon, Kyle J., et al.. (2011). Estrogen negatively regulates epithelial wound healing and protective lipid mediator circuits in the cornea. The FASEB Journal. 26(4). 1506–1516. 83 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact